BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.070
-0.020 (-0.96%)
At close: Dec 5, 2025, 4:00 PM EST
2.030
-0.040 (-1.93%)
After-hours: Dec 5, 2025, 7:48 PM EST
BioXcel Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 0.75 | 2.27 | 1.38 | 0.38 | - | - | |
| Revenue Growth (YoY) | -66.96% | 64.20% | 268.00% | - | - | - | |
| Cost of Revenue | 0.96 | 2.14 | 1.26 | 0.02 | - | - | |
| Gross Profit | -0.21 | 0.12 | 0.12 | 0.36 | - | - | |
| Selling, General & Admin | 20.78 | 34.49 | 83.41 | 68.76 | 54.59 | 24.65 | |
| Research & Development | 29.45 | 30.44 | 84.33 | 91.24 | 52.34 | 57.65 | |
| Operating Expenses | 50.23 | 64.93 | 167.74 | 160 | 106.94 | 82.3 | |
| Operating Income | -50.45 | -64.8 | -167.62 | -159.65 | -106.94 | -82.3 | |
| Interest Expense | -16.62 | -15.13 | -13.31 | -8.21 | -0.04 | -0.03 | |
| Interest & Investment Income | 1.11 | 2.6 | 5.65 | 2.53 | 0.04 | 0.16 | |
| Other Non Operating Income (Expenses) | -2.03 | 20.17 | 0.39 | -0.43 | - | - | |
| EBT Excluding Unusual Items | -67.99 | -57.16 | -174.89 | -165.76 | -106.93 | -82.17 | |
| Merger & Restructuring Charges | -0.23 | -2.44 | -4.16 | - | - | - | |
| Pretax Income | -68.21 | -59.6 | -179.05 | -165.76 | -106.93 | -82.17 | |
| Net Income | -68.21 | -59.6 | -179.05 | -165.76 | -106.93 | -82.17 | |
| Net Income to Common | -68.21 | -59.6 | -179.05 | -165.76 | -106.93 | -82.17 | |
| Shares Outstanding (Basic) | 8 | 3 | 2 | 2 | 2 | 1 | |
| Shares Outstanding (Diluted) | 8 | 3 | 2 | 2 | 2 | 1 | |
| Shares Change (YoY) | 235.79% | 39.21% | 4.00% | 6.23% | 21.63% | 33.11% | |
| EPS (Basic) | -9.09 | -23.51 | -98.33 | -94.67 | -64.87 | -60.63 | |
| EPS (Diluted) | -9.09 | -23.51 | -98.33 | -94.67 | -64.87 | -60.63 | |
| Free Cash Flow | -58.21 | -72.03 | -155.03 | -135.48 | -82.6 | -66.67 | |
| Free Cash Flow Per Share | -7.76 | -28.41 | -85.13 | -77.38 | -50.11 | -49.19 | |
| Gross Margin | -28.19% | 5.43% | 8.70% | 94.67% | - | - | |
| Operating Margin | -6708.24% | -2859.84% | -12146.30% | -42572.00% | - | - | |
| Profit Margin | -9070.61% | -2630.14% | -12974.85% | -44201.87% | - | - | |
| Free Cash Flow Margin | -7741.22% | -3178.60% | -11233.77% | -36128.00% | - | - | |
| EBITDA | -50.14 | -64.5 | -167.3 | -159.32 | -106.64 | -82.11 | |
| D&A For EBITDA | 0.3 | 0.31 | 0.32 | 0.33 | 0.3 | 0.19 | |
| EBIT | -50.45 | -64.8 | -167.62 | -159.65 | -106.94 | -82.3 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.